普伐他汀和吉非齐治疗家族性载脂蛋白B-100缺陷患者:一项两期交叉研究

P S Hansen, H Meinertz, L U Gerdes, I C Klausen, O Faergeman
{"title":"普伐他汀和吉非齐治疗家族性载脂蛋白B-100缺陷患者:一项两期交叉研究","authors":"P S Hansen,&nbsp;H Meinertz,&nbsp;L U Gerdes,&nbsp;I C Klausen,&nbsp;O Faergeman","doi":"10.1007/BF00577757","DOIUrl":null,"url":null,"abstract":"<p><p>Thirty patients with familial defective apolipoprotein B-100 were treated in a two-period (8 weeks each) cross-over study with pravastatin and gemfibrozil. Cholesterol, LDL cholesterol, and apo B were reduced by 20-25% (P < 10(-4)) by pravastatin and by 4-6% by gemfibrozil (pravastatin vs. gemfibrozil: P < 10(-4)). Response to pravastatin was variable and not correlated to gender, age, or apo E genotype. Gemfibrozil lowered triglycerides by 25% (P < 10(-4)) and raised HDL cholesterol by 11%. The effects of pravastatin on these two interrelated variables were significantly smaller. Both drugs increased Lp(a) significantly by about 10%. The LDL cholesterol lowering effect of pravastatin in patients with FDB is similar to that observed in patients with familial hypercholesterolemia.</p>","PeriodicalId":22408,"journal":{"name":"The clinical investigator","volume":"72 12","pages":"1065-70"},"PeriodicalIF":0.0000,"publicationDate":"1994-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF00577757","citationCount":"6","resultStr":"{\"title\":\"Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study.\",\"authors\":\"P S Hansen,&nbsp;H Meinertz,&nbsp;L U Gerdes,&nbsp;I C Klausen,&nbsp;O Faergeman\",\"doi\":\"10.1007/BF00577757\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Thirty patients with familial defective apolipoprotein B-100 were treated in a two-period (8 weeks each) cross-over study with pravastatin and gemfibrozil. Cholesterol, LDL cholesterol, and apo B were reduced by 20-25% (P < 10(-4)) by pravastatin and by 4-6% by gemfibrozil (pravastatin vs. gemfibrozil: P < 10(-4)). Response to pravastatin was variable and not correlated to gender, age, or apo E genotype. Gemfibrozil lowered triglycerides by 25% (P < 10(-4)) and raised HDL cholesterol by 11%. The effects of pravastatin on these two interrelated variables were significantly smaller. Both drugs increased Lp(a) significantly by about 10%. The LDL cholesterol lowering effect of pravastatin in patients with FDB is similar to that observed in patients with familial hypercholesterolemia.</p>\",\"PeriodicalId\":22408,\"journal\":{\"name\":\"The clinical investigator\",\"volume\":\"72 12\",\"pages\":\"1065-70\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/BF00577757\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The clinical investigator\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/BF00577757\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The clinical investigator","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF00577757","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

摘要

30例家族性载脂蛋白B-100缺陷患者接受普伐他汀和吉非齐齐两期(各8周)交叉治疗。普伐他汀可使胆固醇、低密度脂蛋白胆固醇和载脂蛋白B降低20-25% (P < 10(-4)),吉非齐可降低4-6%(普伐他汀vs吉非齐可降低P < 10(-4))。对普伐他汀的反应是可变的,与性别、年龄或载脂蛋白E基因型无关。吉非罗齐降低甘油三酯25% (P < 10(-4)),升高高密度脂蛋白胆固醇11%。普伐他汀对这两个相关变量的影响明显较小。两种药物均可显著提高Lp(a)约10%。普伐他汀在FDB患者中的低密度脂蛋白胆固醇降低效果与家族性高胆固醇血症患者相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study.

Thirty patients with familial defective apolipoprotein B-100 were treated in a two-period (8 weeks each) cross-over study with pravastatin and gemfibrozil. Cholesterol, LDL cholesterol, and apo B were reduced by 20-25% (P < 10(-4)) by pravastatin and by 4-6% by gemfibrozil (pravastatin vs. gemfibrozil: P < 10(-4)). Response to pravastatin was variable and not correlated to gender, age, or apo E genotype. Gemfibrozil lowered triglycerides by 25% (P < 10(-4)) and raised HDL cholesterol by 11%. The effects of pravastatin on these two interrelated variables were significantly smaller. Both drugs increased Lp(a) significantly by about 10%. The LDL cholesterol lowering effect of pravastatin in patients with FDB is similar to that observed in patients with familial hypercholesterolemia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信